Nurix

How Weaker Q1 Results And Advancing Bexobrutideg Trials At Nurix Therapeutics (NRIX) Have Changed Its Investment Story

Nurix Therapeutics, Inc. reported first-quarter 2026 results with revenue of US$6.25 million versus US$18.45 million a year earlier, alongside a wider net loss of US$87.17 million and a basic loss per share of US$0.79 from continuing operations. A...